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Abstract
Continuous antiretroviral therapy is currently the most effective way to treat HIV infection. Unstructured interruptions are
quite common due to side effects and toxicity, among others, and cannot be prevented. Several attempts to structure these
interruptions failed due to an increased morbidity compared to continuous treatment. The cause of this failure is poorly
understood and often attributed to drug resistance. Here we show that structured treatment interruptions would fail
regardless of the emergence of drug resistance. Our computational model of the HIV infection dynamics in lymphoid tissue
inside lymph nodes, demonstrates that HIV reservoirs and evasion from immune surveillance themselves are sufficient to
cause the failure of structured interruptions. We validate our model with data from a clinical trial and show that it is possible
to optimize the schedule of interruptions to perform as well as the continuous treatment in the absence of drug resistance.
Our methodology enables studying the problem of treatment optimization without having impact on human beings. We
anticipate that it is feasible to steer new clinical trials using computational models.
Citation: Mancini E, Castiglione F, Bernaschi M, de Luca A, Sloot PMA (2012) HIV Reservoirs and Immune Surveillance Evasion Cause the Failure of Structured
Treatment Interruptions: A Computational Study. PLoS ONE 7(4): e36108. doi:10.1371/journal.pone.0036108
Editor: Vladimir Brusic, Dana-Farber Cancer Institute, United States of America
Received December 15, 2011; Accepted March 30, 2012; Published April 27, 2012
Copyright:  2012 Mancini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Partial support from the European Union under the EC contract FP6-2004-IST-4, No. 028069 (ImmunoGrid) http://igrid-ext.cryst.bbk.ac.uk/immunogrid/
site/. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: E.Mancini@uva.nl
Introduction
The increase in life expectancy of HIV positive individuals
raised both costs and side effects of combination Anti-Retroviral
Therapy (cART), stimulating research into Structured Treatment
Interruptions (STI). Latest clinical trials on STI [1,2] indicated
they are less effective than continuous treatment. We show that the
STI tested so far in clinical trials would fail regardless of the
emergence of drug resistance and that this failure is caused by HIV
reservoirs and immune evasion.
For many HIV positive individuals treatment interruptions are
unavoidable. Although clinical studies proved that increased risks
are associated to cART interruptions, patient-initiated unstruc-
tured treatment interruptions are still quite common in the clinical
practice [3]. A recent systematic review [4] of cohort studies and
clinical trials indicates a proportion of unstructured treatment
interruptions ranging from 5.8% to 83.1% with a median of
23.1%. The mean duration of cART interruptions ranges from
11.5 days to 18 months with a median of 150 days. The main
reported reasons for treatment interruptions are laboratory
toxicity and clinical side effects. Less frequent arguments are
patient compliance, treatment fatigue, intercurrent illness and
other reasons.
The problem of unstructured interruptions is getting worse
because of the increasing duration of treatment. Recent studies
suggest an earlier use of cART as a way to fight effectively the HIV
epidemics [5,6]. Current cART guidelines defer the treatment to
the time when CD4
+ counts drop below 350 (European guidelines
- EACS) or 500 cells per microliter (US guidelines - DHHS and
IAS-USA) whereas recent studies indicate that an early start of
cART (CD4
+ counts .500 cells per microliter) could significantly
improve survival [5,7–9]. Regardless of the success of anti-
retroviral therapies, HIV’s ability to mutate and evade both
antiviral treatments and vaccines shifted the attention from curing
affected individuals to fighting the epidemics. Some predictive
models investigate the effects of different strategies on the HIV
epidemics [6,10]. Recent clinical investigations [9] indicate that a
more intensive and earlier use of cART is effective in reducing the
spread of the virus. Indeed, another study highlighted the
effectiveness of preventive use of cART in reducing the chance
of being infected in case of sexual contact with a seropositive
individual [11]. Strategies aimed at reducing the spread of
infection not only extend the duration of cART for an infected
individual but also increase the number of individuals simulta-
neously under cART, raising the - already high - global cost of
cART treatments.
STI aimed at discontinuing the therapy according to a schedule
so as to minimize the side effects without losing substantial
protection. In a large, randomized clinical trial [1,2] STI were
associated with an increased risk of death and opportunistic
diseases connected to treatment interruptions. Earlier studies
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36108[12,13] indicated positive results for STI, in some cases associated
to supporting drugs [14]. Subsequently, many clinical studies on
different STI schedules resulted in generally neutral or negative
outcomes [15–17], although the reasons are still not fully
understood. Results from the Staccato randomized trial indicated
substantial drug savings and did not result in increased drug
resistance in the STI arm, while treatment related adverse events
were more frequent with continuous treatment [18].
Hereafter we resort to a computational model to gain a better
understanding of the reasons of STI failure. A number of
mathematical models describe the HIV infection dynamics and
the related immune response. Some of them take into account the
use of cART [19–21]. Most mathematical models use a continuous
description of time, allowing the use of optimal control techniques
to search for the best time to deliver the therapy [22–24]. Recently
a mathematical model searched for the underlying reasons of STI
failure [25]. That model confirms that viral mutation and the
emergence of drug resistant strains may be accelerated by STI,
although only activated CD4
+ cells and macrophages were
considered as possible hosts for the virus. The study of HIV
through cellular automata and agent-based models is also common
[26–31] due to the discrete nature of the biological entities
involved in the phenomena. In this work we use a well-established
and validated agent-based model (ABM) of HIV infection [32–36].
See File S1 for a brief description of the model used in this work.
Our aim is to gain a better understanding of the reasons behind
STI failure: are they inherent to the HIV dynamics or
consequential of other mechanisms like the emergence of drug
resistance? By excluding to model the resistance to the drugs we
restrict the possible causes of STI failure to mechanisms such as
virus reservoirs in macrophages and resting/memory CD4
+ T
lymphocytes. In addition, in this simplified formulation, we search
for an optimal STI and compare it to the optimal one found in a
previous work [32]. A similar attempt to optimize clinical
treatments using in silico modeling has been applied to cancer-
preventing vaccinations [37]. In that case the predictions of the
computational model were validated through specific in vivo
experiments on mice. That paper proved that an integrated in
vivo-in silico approach is able to improve mathematical and
biological models for cancer immunoprevention.
In the present work we investigate treatment interruptions with
two in silico simulations: in the first simulation we test three STI
used in clinical trials and compare their efficacy to that of the
continuous (i.e., uninterrupted) treatment, while in the second
simulation we search for an optimal STI scheduling and compare
it with random treatment and continuous treatment. By ‘optimal
schedule’ we mean the one that less impairs the ability to mount
an immune response while keeping the amount of drugs used to a
minimum. We use the Simulated Annealing (SA) technique to
search for the optimal STI schedule. We simulate the disease
progression for a group of 250 virtual (i.e., in silico) HIV positive
patients. For each group of virtual patients we compare the effects
of different treatment strategies on the HIV infection over a
therapeutic period of 48 weeks, three years after seroconversion.
We finally evaluate the efficacy of each STI schedule by
challenging the immune system of the virtual HIV patients with
a simulated opportunistic bacterial infection at the end of the
treatment.
Results
Optimization results
To quantitatively evaluate the effect of a STI schedule of cART
we define a fitness function that measures the health of the virtual
patient’s immune system and the amount of drugs received over
the 48 weeks period. The fitness function is described in the
Materials and Methods section. We performed 50 SA optimiza-
tions by using different initial conditions. These optimizations
resulted in 50 optimized treatment schedules with an average
fitness score of 2.325 and a standard deviation of 0.012. The
optimal treatment schedules have 29 weeks of therapy on average
and a standard deviation of 3 weeks. The optimized schedules are
shown in a histogram (Figure 1) in which each bin represents the
frequency of a given week of therapy in the optimized schedules.
The histogram shows a peak every 3 weeks spaced out by 2 weeks
in which the drug administration has a lower but still significant
frequency. Due to the requirement of providing a schedule as
regular as possible, we define as ‘‘optimal’’ a schedule having 2
weeks of therapy followed by an interruption of 1 week for 32
weeks after the initial two months. The optimization shows a
different pattern for the initial two months of treatment (Figure 2).
The optimal schedule has 29 weeks of therapy and is shown in
Figure 2. According to our simulations the last 4 weeks of the
therapeutic period have limited importance. In other words, the
effect of cART at later times is somehow less important,
supporting the current opinion that it is more rewarding to
support the immune system with anti-retroviral treatment at
earlier times.
The aim of the treatment was to suppress the HIV viral load
and induce immune restoration, resulting in an immune system
capable of dealing with opportunistic infections. To assess the
efficacy of the optimal therapy indicated by the SA algorithm, we
ran simulations of an opportunistic infection starting immediately
after the therapeutic period. Bacteria were injected in the virtual
patients as soon as the 48 weeks of therapy were over. The
immune system reaction against those bacteria depended on its
efficiency at injection time. We compared the result of the
schedule optimized by the SA algorithm with three different
simulated control groups (Figure 3). In the first group (‘‘Contin-
uous Therapy’’) the drugs were administered every day for a
therapeutic period of 48 weeks as prescribed by the cART
guidelines; in the second group (‘‘Random Therapy’’) the total
amount of drug was equal to that of the optimal therapy but
administration within the therapeutic period was performed
randomly; finally, in the last group, there was no therapy (‘‘Void
Therapy’’). To measure the effectiveness of the optimized STI we
monitored the survival curve in a population of 250 virtual HIV+
patients infected by a bacterium 4 years after their initial HIV
Figure 1. Optimized HAART Histogram: the histogram shows
50 optimized therapeutic schedules. Each bin represents the
frequency of a given week of therapy in the optimized schedules.
doi:10.1371/journal.pone.0036108.g001
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continuous therapy, void therapy, optimal therapy and random
therapy.
Our results show that the optimal therapy provided a survival
rate comparable to the continuous therapy using 40% less drug.
Survival rate for untreated patients was 45.4%. The optimal
therapy performed significantly better than the void one (survival
rate 90% versus 45.4%). The optimal therapy also performed
better than a random therapy with the same amount of drugs (a
survival rate of 90% vs. 81.9%). The latter result indicates that the
schedule identified by the SA algorithm is optimized for both the
amount of medicine and the administration schedule, supporting
the importance of finding a specific scheduling to reduce
therapeutic failures.
Comparison with clinical trials
Even though different structured treatment schedules have been
tested in clinical trials, a comparison with multiple trials is often
difficult due to the heterogeneity of their experimental conditions.
The clinical trials that tested the STI simulated in our work have
different durations and different criteria for the enrollment of
patients. Such diversity makes it difficult to compare their results
with a single optimized schedule. In terms of initial conditions and
treatment duration our simulations can be related to the clinical
trial by Dybul et al. [16]. As in Dybul’s clinical trial, our
simulations have a treatment period of 48 weeks, enroll patients
with similar CD4
+ cells counts (CD4
+ cells .300 cells/mm
3) and
test the STI schedule with 8 weeks of treatment and 4 weeks of
interruption. The main difference is that in our simulations we use
patients that have been never exposed to HAART and thus with a
higher viral load whereas the clinical trial enrolled patients
receiving a 3-drug HAART regimen with HIV RNA levels ,500
copies/mL plasma for .6 months and ,50 copies/mL at
screening.
The parameters that control the pharmacodynamics of HIV in
our model have been tuned by using clinical information from
about twenty-two patients selected at the Clinical Department of
the National Institute of Infectious Diseases ‘‘L. Spallanzani’’ in
Rome [38]. No special tuning has been performed for the model
parameters of the three STI schedules tested in the present work.
For this reason we can validate our model results by comparing
the simulations for both continuous treatment and the structured
treatment interruption with data from Dybul’s clinical trial. Those
data consists of the median and range of CD4
+ cell counts at
baseline, at week 40 and at week 48 of the treatment period
observed in 52 patients randomized in the continuous and STI
arm of the clinical trial. In (Figure 4) we compare the simulations
results with the values observed in the clinical trial. Simulated
CD4
+ cell counts are within the ranges observed in the clinical
trial. In Table S1 we show the variation of immunological
parameters for all the schedules tested in our virtual cohort. In the
Figure 2. At time 0 a virtual patient is infected with HIV. The
therapeutic period of 48 weeks starts after 3 years of untreated
infection (day 1096). The optimal therapy is shown in the figure. At the
end of the 48 weeks of therapy we inject a fixed amount of bacteria in
the virtual patient, challenging his immune system. The patient dies if
the antigens exceed a threshold of 4610
6 bacteria/ml. An efficient
therapy is capable of restoring the patient’s immune system enough to
contain the bacterial infection.
doi:10.1371/journal.pone.0036108.g002
Figure 3. Survival curves: percentage of survivors over time in a population of 250 HIV+ virtual patients. 30 days after bacterial
challenge survival rates are the following: continuous therapy 91.53%, optimal therapy 90%, random therapy 81.85% and void therapy 45.38%. A
reduction of 40% of the drug intake corresponds to less than 5% reduction in the survival rate.
doi:10.1371/journal.pone.0036108.g003
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virtual cohort at week 40 and week 48 of the treatment period.
Results of the STI strategies tested in clinical trials are shown in
Figure 5. As observed in the clinical trials, all the STI strategies are
associated with an increased number of deaths compared to the
continuous treatment. The ratio of deaths associated to the ‘‘Week
On/Week Off’’ strategy over that of continuous therapy is 1.95 at
the end of the 30 days after opportunistic bacterial infection. The
same ratio is 3.52 for the ‘‘4 Weeks On/4 Weeks Off’’ strategy and
2.05 for the ‘‘8 Weeks On/4 Weeks Off’’. We observe a ratio of
deaths of 1.19 for the Optimal therapy and 2.14 for the Random
therapy.
The effects of the different STI on virological and immunolog-
ical parameters are shown in (Figure 6). The parameters that show
the strongest correlation with the survival of the virtual patients in
the long term are CD4
+ cell count and provirus levels. The levels
of provirus seem to be responsible for the failure of STI treatment
as much as the CD4
+ cells count. The ‘‘4 Weeks On/4 Weeks Off
’’ schedule has the worst survival because of the high level of
provirus even though it shows a CD4
+ cells count comparable to
that of the ‘‘Week On/Week Off ’’ STI. The difference in the ratio
of deaths associated to ‘‘ 8 Weeks On/4 Weeks Off ’’ and the
optimal STI (2.05 versus 1.19) should be due to their difference in
the level of provirus, since both schedules show comparable CD4
+
cell counts. These results lead us to point out the importance of
HIV reservoirs as one of the main causes of STI failure. As
expected, a treatment interruption longer than 10 days leads to a
viral rebound and a decrease in CD4
+ cell count. We observe that
the viral rebound is proportional to the duration of the
interruption. Treatment interruptions of one or two weeks have
a smaller viral rebound whereas for longer interruptions the viral
load reaches levels comparable to the ones before treatment (data
not shown).
For both optimal and continuous treatment the outcome of the
opportunistic infection is correlated more to the level of provirus
than to the level of CD4
+ lymphocytes. For all other schedules it
seems that both CD4
+ and provirus are relevant in determining
fatal outcomes of the bacterial infection. In Figure 7 we show the
CD4
+ cell counts versus provirus level of the 250 virtual patients
for each of the treatment schedules tested in the present work. For
each STI schedule we separate the 250 virtual patients in two
groups (survivors and casualties) depending on the outcome of the
opportunistic infection. We perform a Kolmogorov-Smirnov two-
sample test to compare the distributions of the CD4
+ cell counts at
the end of the treatment period in both groups. The null
hypothesis is that the CD4
+ cell counts in the group of survivors
and the one in the group of casualties are from the same
distribution. For all the treatment schedules tested, except the
optimal and continuous treatment, the null hypothesis is rejected
with p-values between 1.1*10
25 and 1.6*10
22. Surprisingly for the
optimal and continuous treatment the CD4
+ cell count are not
related to the outcome of the opportunistic infection (p-value 0.29
and 5.1*10
22). We perform the same test to compare the
distributions of provirus in survivors and casualties. In this case
the null hypothesis is rejected for all the schedules with p-values
between 9.1*10
212 and 1.5*10
22.
Discussion
The three STI strategies (‘‘Week On/Week Off’’, ‘‘4 Weeks
On/4Weeks Off’’ and ‘‘8 Weeks On/4Weeks Off’’) have lower
performances compared to continuous treatment regardless of the
emergence of drug resistance since the ratio of death associated to
a clinically tested STI strategy over that of continuous treatment is
between 1.95 and 3.52. Since in the model we don’t allow HIV to
develop resistance to cART drugs, the failure of STI seems to be
inherent to the HIV infection dynamics, rather than caused by the
emergence of drug resistant strains. We conclude that the amount
of HIV reservoirs both in macrophages and latently infected
resting/memory CD4
+ T lymphocytes are sufficient to cause a
failure of the STI schedules tested so far in clinical trials regardless
of drug resistance. This observation may have relevant implica-
tions for the design of future treatment strategies. Indeed, efforts
directed towards the reduction of the size of HIV reservoirs in
humans, might facilitate the adoption of subsequent strategies
aimed at reducing the antiretroviral treatment exposure, such as
STI or treatments with less drugs [39].
We also show that, without the emergence of drug resistance, it
is possible to find an optimized STI whose efficacy is close to that
of a continuous treatment with a reduction of 40% in drug
Figure 4. Model validation: CD4
+ cell counts/mm
3 at three
different time points (Baseline, Week 40 and Week 48). In the
upper panel we compare the median CD4
+ cell counts of 250 virtual
patients with the data of real patients from the continuous treatment
arm of Dybul’s clinical trial. In the lower panel we compare the median
CD4
+ cell counts of 250 virtual patients with the data of real patients
from the STI arm of Dybul’s clinical trial.
doi:10.1371/journal.pone.0036108.g004
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On/4 Weeks Off’’ STI we show that adherence to the optimal
treatment schedule is more important than the amount of drug
taken over the treatment period. The efficacy of random therapies
with the same amount of drug of the optimal treatment is sensibly
lower than that of optimal treatment. Results indicate a ratio of
death of 2.14 for the random treatment instead of 1.19 observed
for the optimal. We conclude that the SA optimization was
successful in identifying an optimal schedule of drug administra-
tion for the set of conditions studied in this work.
The result obtained in a previous work [32] on a shorter
therapeutic period (6 months) and optimized by using a genetic
algorithm indicated an optimized therapy with a week-on week-off
pattern after a period of about 2 months of continuous therapy.
The initial period of continuous therapy is not necessary according
to our study, possibly because the immune system is not
compromised enough to require an initial strong recovery phase.
In the previous study the percentage of survivors for full and
optimal therapy was comparable (34.1% and 30.5% respectively)
whereas random and void therapy had lower performances
(21.9% and 20.2%). The differences in the optimized treatments
indicate that the best therapeutic strategy changes with the
progressive damage that HIV infection inflicts on the immune
system. Since at 3 years post infection the immune system is
usually not severely compromised, in the present study the
percentage of survivors is higher than the one observed in the
previous study in which the therapy started almost 8 years after
HIV infection. An interesting difference is the effect of random
therapy. In our study we notice that a random therapy has less
negative effects if the patient receives early (CD4
+ cell counts
.500 cell/mm
3) cART. If treatment starts later random therapy
has virtually no effect, as shown in [32]. This result indicates that
unstructured interruptions have a less negative effect on the short
term when the immune system is still healthy but further
investigation is required to evaluate their effects in the long term.
The increased risk of opportunistic infections associated to
provider-directed structured therapeutic interruptions led to
abandoning this strategy in favor of the safety of a continuous
treatment. Yet continuous treatment is not always possible as
suggested by the proportion of patient-initiated unstructured
interruptions. Since new studies suggesting the beneficial effects of
early treatment may increase the duration of cART in a patient’s
life, a further growth of the already common unstructured
interruptions can be foreseen. Moreover, so far, no clinical study
has compared the risk of opportunistic infections associated with
unstructured interruptions to the risk associated with STI. Finally,
the sustainability of life-long antiretroviral therapy at global level,
both from an economic and toxicity points of view, still represents
a major challenge. For these reasons, exploring the mechanisms
behind the failure of structured therapeutic interruptions and the
possible optimal STI is still an open topic.
The ethical problems associated to further studies of STI in light
of the previous failures make the use of modeling techniques
appealing. The possibility of simulating STI in silico to predict the
success or failure of a given STI strategy is a powerful tool that can
support the design of clinical studies without having impact on
human beings. The optimization of treatment interruptions is
another clear example of the usefulness of modeling approaches to
foster the understanding of complex problems.
For the HIV infection the lack of fully predictive animal models
[40] makes it difficult to accurately validate the prediction of
computational models. It is very difficult to address the ethical
implications of testing computational predictions on humans,
given the potential loss of human lives that could be caused by a
wrong prediction. Yet, clinical trials are still needed and any tool
that could be used to assist those trials should be considered.
Regardless of the difficulties in validating the predictions of our
model, our results can be used to orientate qualitatively the design
of clinical trials. In silico simulations could be used to predict if a
STI schedule might fail because of the size of the HIV reservoir
regardless of the emergence of drug resistance. In this way clinical
trials could be directed toward schedules with a higher chance of
success.
Figure 5. STI Survival curves for different STI strategies: percentage of survivors over time in a population of 250 HIV+ virtual
patients. 30 days after bacterial challenge, survival rates are the following: Week On/Week Off STI 83.60%, 8 Weeks On/4 Weeks Off 82.66% and 4
Weeks On/4 Weeks Off 70.28%. Survival rates for continuous therapy and void therapy are 91.53% and 45.38% respectively.
doi:10.1371/journal.pone.0036108.g005
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In silico approach
In this paper we adopt a two phases approach similar to the one
used in Castiglione et al. 2007 [32] to study the existence of an
optimal treatment that minimizes the drug administration without
compromising the immune system response to HIV. Firstly we
search for the optimal STI schedule (‘‘optimal therapy’’) by using
the simulated annealing optimization algorithm. In this phase,
looking at the conditions of the immune system at the end of the
therapeutic period, we evaluate the potentially administered
therapeutic schedule by means of computer simulations. The SA
algorithm is applied to search for the optimal schedule of cART
interruptions that maximizes both the immune system recovery
and viral control and, at the same time, minimizes the amount of
drugs used in a therapeutic period. Secondly, once we have found
the optimal schedule, we test it by challenging the immune system
with an opportunistic infection simulated by introducing a
bacterium in a group of 250 virtual patients. Therefore, we
compare the survival curves of the different control groups with
the survival curve of the optimal therapy. In the first control group
patients have a continuous course of therapy (i.e., uninterrupted)
for the whole period (‘‘continuous therapy’’). Patients of the second
control group receive the same amount of medicine as in the
optimal therapy, but the drugs are randomly administered in time
(‘‘random therapy’’). The last control group consists of untreated
patients (‘‘void therapy’’), that is, patients that do not receive
therapy at all. Performing this test in silico allows us to use the same
virtual patients for each group, whereas in clinical trials the control
groups consist of different individuals. Such choice enables us to
directly relate the survival of rates of each group to the effect of the
different therapies.
In addition to the search for an optimal STI we also study the
effects of STI strategies tested in clinical trials by comparing their
effect on the HIV dynamics of the virtual patients over a period of
48 weeks of treatment. As control groups for this experiment we
use groups of 250 virtual patients under continuous treatment and
void treatment. Since the model does not include drug resistance,
Figure 6. Simulation results. Median CD4
+ cells count (upper panel) and provirus levels (lower panel) of the 250 virtual patients during the 48
weeks treatment period. In each panel we show the different STI tested in this study, the optimal therapy and the continuous therapy. The levels of
provirus seem to be responsible for the failure of STI treatment as much as the CD4
+ cells count. The ‘‘4 Weeks On/4 Weeks Off’’ schedule has the
worst survival curve because of the high level of provirus even though it has a CD4
+ cells count comparable to that of the ‘‘Week On/Week Off’’ STI.
doi:10.1371/journal.pone.0036108.g006
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dynamics of the immune response to the HIV virus and in
particular to the action of antibody producing B lymphocytes and
to the CD4
+ and CD8
+ T cells.
Quantitative evaluation of STI
The simulation starts at time zero with an injection of HIV viral
particles and the HIV infection progresses untreated for three
years. At that point the disease is already in its chronic phase and
we start a therapeutic period of 48 weeks. During the therapeutic
period we administer the cART according to a given schedule
represented by TherStr, a 48-bit-long string, where a 0 stands for a
week without therapy (i.e., an interruption) and a 1 stands for a full
week of therapy (Figure 8). We assume the efficacy of the therapy
to drop to zero during an interruption so that the HIV life cycle
may progress unhindered through all its stages during the
interruptions. Most cART regimens administer a daily cocktail
of at least three drugs, commonly two RTIs and one PI. Although
we could optimize the therapy on a daily basis, we decided to
constrain the minimum administration/interruption period to one
week. Note that this is not a fundamental limitation in our
approach, but rather a practical one since no patient would be
able to follow a one-year-long therapeutic schedule changing on a
daily basis. In addition this choice allows a direct comparison with
a previous study based on a genetic algorithm. Another constraint
to the simulated cART dictated by medical practice is that RTI
and PI drugs are always administered at the same time. At the end
of the 48 weeks we measure the efficacy of the therapy by assigning
a score given by our fitness function. At the beginning of the
therapeutic period, the average CD4
+ count measured in the
virtual patients is about 500 cells per microliter.
To quantitatively evaluate the effect of a STI schedule of cART
we define a fitness function Fi for the i
th virtual patient. The fitness
function measures the health of the virtual patient’s immune
system as the outcome of a simulation and the amount of drugs
received over the 48 weeks period. Since the whole immune/HIV
dynamics depends on the therapy administered, the fitness score is
a function of TherStr.F i is the sum of three terms Hi,D i and Zi.
Figure 7. Survivors and Casualties. In each panel we show the CD4
+ cell counts versus provirus of the 250 virtual patients at the end of the
treatment period. The black markers indicate the patients that survived the opportunistic bacterial infection, whereas the red markers indicate the
patients that died within 30 days of the bacterial infection.
doi:10.1371/journal.pone.0036108.g007
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the average of the sum of both virus contained in infected cells
and free viral particles divided by the viral set point here
defined as the sum of free virus and virus in infected cells at
time the treatment starts ts;
N Di is a measure of the fitness of the immune system and is given
by the average of the ratio between the CD4
+ count of the
healthy individual (i.e., CD4
+ count at time=0, just before the
infection) and the CD4
+ count during the treatment period;
N Zi measures the amount of drugs used as the ratio between the
number of weeks of active therapy and the 48 weeks of
treatment.
In order to partially account for inter-patient variability, the
optimization algorithm tries to minimize F, the average fitness
score of eight virtual patients.
F~
X 8
i~1
Fi~
X 8
i~1
HizDizZi ð1Þ
where
Hi~
1
(te{ts)
X te
t~ts
Hi(t,TherStr)
Hi(ts)
ð2Þ
Di~
1
(te{ts)
X te
t~ts
Di(t~0)
Di(t,TherStr)
ð3Þ
Zi~
zi(TherStr)
(te{ts)
ð4Þ
In the formulas above ts indicates the time the therapy starts (three
years post infection); te the time the therapy ends (i.e., 48 weeks
after ts); Hi(t,TherStr) is the sum of free virions and proviral HIV in
infected cells; Di(t, TherStr) is the T helper cell count in the
simulated space and zi(t, TherStr) is a function such that zi(t)=1 if
the therapy is active at time t, zero otherwise. Minimizing the
fitness function implies decreasing the viral load and the amount of
drugs used, whereas increasing the CD4
+ cell count over a period
of 48 weeks. C-ImmSim uses a time-step corresponding to 8 hours
of real life.
Simulated annealing optimization
To find the optimal schedule of the cART during the 48 weeks
therapeutic period we use a Simulated Annealing algorithm [41].
To optimize the STI we perform in silico experiments on a test
group of 8 virtual patients. The size of the test group is
purposefully chosen equal to the number of cores available in
each node of the computer cluster used to perform the
optimization. This choice allows us to simulate in parallel the
HIV infection on 8 virtual patients, by performing the computa-
tion on a single node.
We adapted the classic simulated annealing algorithm to take as
input a therapeutic schedule in the form of a 48 bits string where
each bit represents a week of therapy. We define an algorithm to
update the therapeutic schedule that modifies the previous
schedule by adding, removing or shifting 1 week of therapy (1
bit). By using this algorithm we assume that two consecutive
configurations in the Markov chain have comparable fitness scores
(i.e., the energy of two consecutive configurations is comparable),
which is a requirement for a correct annealing optimization.
The simulated annealing is characterized by a set of parameters
described in Table S2. For the annealing we resort to a geometric
cooling schedule [42]. We tested also logarithmic and adaptive
cooling schedules. The logarithmic cooling was soon discarded due
to the long computational times required and the adaptive did not
result in a better convergence.
A similar optimization problem has been studied in the past by
following an approach based on a genetic algorithm (GA) [32].
The GA study looked for the optimal therapy over a period of six
months starting after 7.5 years post infection. One of the main
differences between the present work and the previous one [32] is
that we reduce the time between seroconversion and treatment
from 7.5 to 3 years. This reduction allows considering the positive
effect of early cART, but increases the difficulty of the
optimization because the effect of cART on CD4 recovery is
dampened by the healthier immune system at the time of
treatment initiation. Another important difference is that we
attempt to optimize the schedule over a longer period (close to 1
year) instead of just 24 weeks. Extending the therapeutic period to
one year increases the complexity of the optimization problem. In
the previous study the state space had 2
24 possible configurations.
In the present work we face a state space of 2
48 configurations.
Doubling the therapeutic period allows to test if the optimal STI
can yield results similar to those observed in the shorter STI
previously studied [32]. Clinical studies on STI indicated a
reduction of the benefits over longer time periods [15,16,43]. By
using an extended period of STI we have the chance to verify if we
observe a similar behavior in the model.
In each iteration of the optimization algorithm we evaluated the
fitness function as the average among N=8 virtual patients. The
evaluation of the fitness of a given STI schedule required the
simulation of 4 years of HIV infection dynamics in each individual
patient. Most of the computational time is due to the C-ImmSim
simulations, whereas the annealing algorithm has a relatively small
impact on the computation time. The longest annealing
optimizations use MAXITER equal to 27000 and take about 15
days to complete (Figure 9) using a L5520 eight-core processor
having a clock rate equal to 2.26 GHz.
We explore stochastically the configuration space of 2
48
different therapeutic schedules. We stop the optimization when
the standard deviation of the fitness score for the last homogeneous
Markov chains (i.e., parameter MARKOVCHAIN in the Table S2
in Supporting Information) is lower than an arbitrary threshold set
equal to 10
24. Each instance of the optimization algorithm results
in an optimized schedule and a corresponding fitness score. We
Figure 8. HAART schedule is represented as a 48-bit string. In
the string, the j
th bit set to 1 means that during the j
th week the HAART
is administered to the patient.
doi:10.1371/journal.pone.0036108.g008
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As usual with most stochastic algorithms we do not have any
warranty that a better solution could not be found by continuing
the search.
Supporting Information
File S1 Description of the computational model used to
simulate HIV infection in virtual patients.
(DOC)
Table S1 Variations of immunological and virological
parameters: In the upper part of the table we report the
data from Dybul’s clinical trial [16]. In the lower part of the
table we show the results of our simulations. For each treatment
schedule tested in our simulations we report the median value for
the most important immunological and virological parameters. In
parentheses we report the minimum and maximum values
observed in the population of 250 virtual patients. For the viral
load measurement ND indicates level of infectious virions below
the detection level (,50 virions/ml).
(DOC)
Table S2 Parameters of the simulated annealing algo-
rithm.
(DOC)
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